IP Library › Granted Patent US 7,435,570
Granted Patent B2
US 7,435,570 · App. 10/916,369 · Granted Oct 14, 2008

Thermostable peroxide-driven cytochrome P450 oxygenase variants and methods of use

Assignee: California Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,570
App. No.
10/916,369
Granted
Oct 14, 2008
Kind
B2
Abstract

The invention relates to novel variants of cytochrome P450 oxygenases. These variants have at least one mutation improving their ability to use peroxide as an oxygen donor as compared to the corresponding wild-type enzyme. The variants also have at least one mutation improving thermostability as compared to the parent enzyme or corresponding wild-type enzyme. Preferred variants include cytochrome P450 BM-3 heme domain variants having L52I, I58V, F87A, H100R, S106R, F107L, A135S, M145A/V, A184V, N239H, S274T, L324I, V340M, I366V, K434E, E442K, and/or V446I amino acid substitutions.

Claims (18)

1. An isolated variant of a cytochrome P450 BM-3 comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO:13, the variant comprising a first mutation at amino acid residue M145 of SEQ ID NO:13, and a second mutation at amino acid residue N239, of SEQ ID NO:13, wherein the variant has peroxygenase activity.

2. The isolated variant of claim 1 , comprising mutations in at least three amino acid residue selected from K9, I58, F87, E93, H100, F107, K113, A135, M145, 145A, A184, N186, D217, M237, E244, S274, L324, 1366, K434, E442, and V446 of SEQ ID NO:13, and mutations in at least three amino acid residues selected from L52, S106, N239, and V340 of SEQ ID NO:13.

3. The isolated variant of claim 1 , comprising a mutation in L52, I58, F87, H100, S106, F107, A135, A184, N239, S274, L324, V340, 1366, K434, E442, and V446 of SEQ ID NO:13.

4. The isolated variant of claim 1 , wherein the variant cytochrome P450 BM-3 does not include a reductase domain.

5. The isolated variant of claim 1 , wherein the variant has a higher thermostability than a wild-type P450 BM-3.

6. The isolated variant of claim 1 , wherein the variant has a higher thermostability than a wild-type cytochrome P450 BM-3 heme domain.

7. The isolated variant of claim 1 , wherein the first mutation comprises an M145A or M145V mutation.

8. The isolated variant of claim 1 , wherein the second mutation comprises N239H.

9. The isolated variant of claim 1 , wherein the variant comprises at least 6 mutations selected from K9I, L52I, I58V, F87A, F87S, E93G, H100R, S106R, F107L, K113E, A135S, M145A, M145V, A184V, N186S, D217V, M237L, N239H, E244G, S274T, L3241, V340M, 1366V, K434E, E442K, and V4461 of SEQ ID NO:13.

10. The isolated variant of claim 1 , wherein the variant comprises the mutations L521, 158V, F87A, H100R, S106R, F107L, A135S, A184V, N239H, S274T,L324I, V340M, I366V, K434E, E442K, and V446I of SEQ ID NO:13.

11. An isolated variant of a parent cytochrome P450 oxygenase heme domain, the parent cytochrome P450 oxygenase heme domain and having at least 95% sequence identity to SEQ ID NO:13; and the variant comprising a first mutation no more than 10 Angstroms from the first mutation, the second mutation promoting a higher thermostability in the variant, wherein the polypeptide has oxygenase or peroxygenase activity.

12. The isolated polypeptide of claim 11 , wherein the polypeptide has a higher capability of using peroxide as an oxygen donor than a wild-type cytochrome P450 oxygenase.

13. The isolated polypeptide of claim 11 , having a T 50 higher than a wild-type cytochrome P450 oxygenase.

14. The isolated variant of claim 7 , comprising a third mutation at a residue selected from the group consisting of K9, I58, F87, E93, H 100, F107, K113, A135, A184, N186, D217, M237, E244, S274, L324, I366, K434, E442, V446 and any combination thereof of SEQ ID NO:13.

15. The isolated variant of claim 14 , wherein the third mutation comprises K9I, I58V, F87A, F87S, E93G, H100R, F107L, K113E,A135S,A184V, N186S, D217V, M237L, E244G, S274T, L3241, 1366V, K434E, E442K, V446I and any combination thereof.

16. The isolated variant of claim 8 , comprising a fourth mutation at a residue selected from the group consisting of L52, S 106 and a combination thereof of SEQ ID NO:13.

17. The isolated variant of claim 16 , wherein the fourth mutation comprises L52I, S106R or a combination thereof.

18. The isolated variant of claim 1 , comprising 96, 97, 98, or 99% identity to SEQ ID NO:13.

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2004
From: ARNOLD, FRANCES H.; CIRINO, PATRICK C.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 015904/0584 →
Continuity (2)
Provisional Application 6049430900 · Aug 11, 2003
Related Publication 20050037411A1 · Feb 17, 2005